NYSE Arca · ARMP
Armata Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARMP: Nov 11, 2026
Armata Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.57. The reported EPS for the same quarter last year was $-0.42.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.57 | $-0.57 | $-0.57 | 1 |
| Dec 2026 | $-0.57 | $-0.57 | $-0.57 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Sep 23, 9:39 AM EDTArmata Gets $3.7M DoW Funding For AP-SA02 Phase 3 Development; Stock Down(RTTNews) – Armata Pharmaceuticals (ARMP) said it has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War (DoW) to support the Phase 3 development program for AP-SA02 in complicated Staphylococcus aureus bacteremia (SAB).
- RTTNews · Sep 14, 8:22 AM EDTArmata Wins FDA Breakthrough Therapy Designation For AP-SA02 In Complicated SAB; Stock Up(RTTNews) – Armata Pharmaceuticals, Inc. (ARMP) announced that the U.S. FDA has granted Breakthrough Therapy designation to AP-SA02, the company's intravenously administered multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (SAB), includi
- RTTNews · Sep 3, 8:09 AM EDTArmata Pharmaceuticals Advances Phage Therapy Research With New Ar-KM Publication(RTTNews) – Armata Pharmaceuticals, Inc. (ARMP), announced a new publication in the Journal of Molecular Biology providing structural insights into Ar-KM, a phiKMV-like bacteriophage targeting Pseudomonas aeruginosa.
- Zacks · Jul 21, 7:05 AM EDTArmata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- RTTNews · Jul 20, 11:01 PM EDTTop Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch(RTTNews) – Today's top biotech gainers include Zhengye Biotechnology, a veterinary vaccine manufacturer, which surged, easing Nasdaq delisting concerns; Advanced Biomed, which gained after withdrawing its planned U.S. securities offering and reducing potential dilution concerns;
- RTTNews · Jul 13, 8:35 AM EDTArmata Gets FDA Agreement On Pediatric Plan For AP-SA02 In SAB(RTTNews) – Armata Pharmaceuticals, Inc. (ARMP), a late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics, announced that the U.S. FDA has agreed to its Initial Pediatric Study Plan (iPSP) for AP-SA02. The plan establishes the regulatory
- RTTNews · Jun 23, 10:32 AM EDTArmata Receives $2.5 Mln From DoD For AP-SA02 In Treating Bacteremia; Phase 3 Planned For H2 2026(RTTNews) – Armata Pharmaceuticals Inc. (ARMP), a late clinical-stage biotechnology company, on Tuesday announced the receipt of $2.5 million in non-dilutive funding from the U.S. Department of Defense (DoD) to develop the company's lead drug candidate AP-SA02 for treating compli
- Fintel · Apr 15, 7:41 PM EDTArmata Pharmaceuticals (ARMP) Price Target Increased by 16.67% to 17.85The average one-year price target for Armata Pharmaceuticals (NYSEAM:ARMP) has been revised to $17.85 / share. This is an increase of 16.67% from the prior estimate of $15.30 dated April 7, 2026. The price target is an average of many targets provided by analy
- RTTNews · Mar 19, 8:07 AM EDTArmata Pharmaceuticals Delays Q4 And Full-year Results; Provides Business Updates(RTTNews) – Armata Pharmaceuticals, Inc. (ARMP) said on Thursday that it will delay reporting its fourth-quarter and full-year 2025 results as it needs more time to complete financial reporting, and expects to file its annual report by March 31, 2026.
- RTTNews · Feb 27, 9:17 AM ESTWeekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX(RTTNews) – This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial s
- Fintel · Feb 24, 7:00 PM ESTArmata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30The average one-year price target for Armata Pharmaceuticals (NYSEAM:ARMP) has been revised to $15.30 / share. This is an increase of 25.00% from the prior estimate of $12.24 dated February 1, 2026. The price target is an average of many targets provided by an
- Fintel · Jan 14, 4:17 PM ESTArmata Pharmaceuticals (ARMP) Price Target Increased by 33.33% to 12.24The average one-year price target for Armata Pharmaceuticals (NYSEAM:ARMP) has been revised to $12.24 / share. This is an increase of 33.33% from the prior estimate of $9.18 dated December 18, 2025. The price target is an average of many targets provided by an
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Armata Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.